Navigation Links
Medarex Announces Ipilimumab Program Continues to Move Forward
Date:4/3/2008

ce or presence of CTLA- 4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells.

Comprehensive Clinical Trial Program for Ipilimumab

Ipilimumab is being developed through a joint partnership between Bristol- Myers Squibb and Medarex. Based on nonclinical and clinical studies showing that antibody blockade of CTLA-4 plays an important role in sustaining an active immune response to fight cancer, Bristol-Myers Squibb and Medarex are pursuing a broad clinical development program with ipilimumab evaluating its potential use in advanced metastatic melanoma, as well as prostate, lung, pancreatic, bladder, breast, lymphoma and leukemia cancers. More than 2,000 patients have been treated with ipilimumab as a monotherapy or in combination with other agents in clinical trials.

For further information about ipilimumab clinical trials, please visit http://www.clinicaltrials.gov.

About Advanced Melanoma

Melanoma is a form of skin cancer characterized by the uncontrolled growth of pigment-producing cells (melanocytes) located in the skin. As with many cancers, it is more difficult to treat once the disease has spread beyond the skin to other parts of the body by way of the bloodstream or the lymphatic system (metastatic disease). Melanoma accounts for about three percent of skin cancer cases, but it causes most skin cancer deaths. The American Cancer Society estimates that in 2007 there will be 59,940 new cases of melanoma in the U.S., and about 8,110 people will die of this disease.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inf
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015 According to a ... Product (Consumables, Instruments, Services), by Test Type (Indirect, Enzyme-based, ... Cytometry), by End Users - Global Forecast to 2020", ... expected to reach $736.85 Million by 2020 from $452.36 ... Browse 71 market data Tables and ...
(Date:5/22/2015)... --  InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the ... announced that its CGuard TM Embolic Prevention System reported ... Piotr Musialek , at the EuroPCR conference on ... PARADIGM, an investigator-initiated P rospective evaluation of ... revascularization I n symptomatic and increased-risk asymptomatic carotid ...
(Date:5/22/2015)... May 22, 2015 Today, Rhodes Pharmaceuticals ... system stimulant indicated for the treatment of Attention-Deficit/Hyperactivity ... Summer 2015. The announcement comes ... from the U.S. Food and Drug Administration (FDA). ... formulation of methylphenidate capsule with an onset of ...
Breaking Medicine Technology:Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
(Date:5/22/2015)... MA (PRWEB) May 22, 2015 ... Hart, MS/CCC, SLP, RAC-CT, CHHRP-QT, Vice President of ... “A very important ‘language’ that impacts how care ... the leader in long term care reimbursement, operations ... education programs and talent management, launches a new ...
(Date:5/22/2015)... Memorial Day weekend is typically considered the ... offering some tips to help promote safe travel. , According ... 383 traffic fatalities this Memorial Day weekend. Amica is sharing ... Safety Association: , , Always wear ... a seatbelt, whether they’re driving or riding along as a ...
(Date:5/22/2015)... ZH Healthcare (ZH), a ... that Bill Lane, joins ZH’s Advisory Board. ... first of its kind, Freemium SaaS, Electronic Health ... Records (EHR) with an integrated practice management system ... portal, and more. Combined with its Revenue Cycle ...
(Date:5/22/2015)... May 22, 2015 Medivo, Inc., a leader ... Rates and Genotype Results in ‘Baby Boomers’ Screened for HCV ... Nationwide Lab Test Database” at Digestive Disease Week, May 16-19, ... Affairs and Analytics team members Carol Smyth, MB; Jason Bhan, ... Parker, MSI, along with Nancy Reau, MD from the University ...
(Date:5/22/2015)... FL (PRWEB) May 22, 2015 DMG ... Begley, Jr., scheduled to broadcast on Friday, May 29, ... via Discovery Channel. , In this episode Innovations will ... get back to business quickly through disaster recovery and ... a company that works collaboratively to develop and deliver ...
Breaking Medicine News(10 mins):Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2Health News:New Episode of Innovations Airing Friday, May 29, 2015 Via Discovery Channel 2
... with hepatitis C are fine for patients with the ... News) -- Every year, hundreds of kidneys are thrown ... but they could help many hepatitis C-infected patients waiting ... fact, since 1995, more than 3,500 kidneys infected with ...
... journal Cell , a Cell Press publication, reveal a new ... and quickly in the tumors of cancer patients undergoing therapy. First ... enter a drug-tolerant state. But there,s some potentially very good news ... or block cancer,s drug resistance. "The problem with cancer ...
... Finding shows drug resistance can be lost, treatment can work ... identified a mechanism by which certain tumor cells that become ... , The discovery may lead to new ways to combat ... new study, published online April 1 in the journal ...
... Although new developments in the management of spinal cord injuries ... condition is more likely to involve a multidisciplinary approach, drawing ... published in the April 2010 issue of the Journal ... ). Each year, approximately 12,000 men ...
... ... in the hands of college students and challenging them to do good in their community in ... Your Community? , ... April 1, 2010 -- 5-Hour Energy® is traveling to campuses across the nation to put its ...
... ... real-time a key differentiator , ... Marlborough, MA (PRWEB) April 1, 2010 -- LogMatrix, a provider of log management, threat management ... currently using the LogMatrix LogCenter solution to capture and report on over 2 billion events ...
Cached Medicine News:Health News:Hundreds of Donor Kidneys Tossed Away Each Year 2Health News:Hundreds of Donor Kidneys Tossed Away Each Year 3Health News:Tumor cells seek temporary shelter from cancer drugs 2Health News:Tumor cells seek temporary shelter from cancer drugs 3Health News:Study Suggests How Some Cancers Resist Treatment 2Health News:Study Suggests How Some Cancers Resist Treatment 3Health News:Next decade offers promise for treatment of spinal cord injuries 2Health News:5-Hour Energy Challenges College Students To Make a Difference In Their Community 2Health News:LogMatrix Log Management Solution Easily Supports Customer's Extreme Scalability and Data Retrieval Requirements 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: